For HNSCC, most studies exploring combination therapies that include CTLA-4 inhibitors incorporate conventional treatment options, such as radiotherapy or the inhibition of the PD-1/PD-L1 axis. Here, CTLA4 is linked to head and neck squamous cell carcinoma.